- Home
- QFIN vs TARS Comparison
QFIN vs TARS Comparison
Compare QFIN & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QFIN
- TARS
- Stock Information
- Founded
- QFIN 2016
- TARS 2016
- Country
- QFIN China
- TARS United States
- Employees
- QFIN N/A
- TARS N/A
- Industry
- QFIN Finance: Consumer Services
- TARS Medicinal Chemicals and Botanical Products
- Sector
- QFIN Finance
- TARS Health Care
- Exchange
- QFIN Nasdaq
- TARS Nasdaq
- Market Cap
- QFIN 3.4B
- TARS 2.8B
- IPO Year
- QFIN 2018
- TARS 2020
- Fundamental
- Price
- QFIN $23.66
- TARS $69.99
- Analyst Decision
- QFIN Strong Buy
- TARS Strong Buy
- Analyst Count
- QFIN 2
- TARS 7
- Target Price
- QFIN $45.10
- TARS $69.43
- AVG Volume (30 Days)
- QFIN 2.0M
- TARS 583.6K
- Earning Date
- QFIN 11-18-2025
- TARS 11-04-2025
- Dividend Yield
- QFIN 7.14%
- TARS N/A
- EPS Growth
- QFIN 68.82
- TARS N/A
- EPS
- QFIN 7.06
- TARS N/A
- Revenue
- QFIN $2,618,582,596.00
- TARS $295,521,000.00
- Revenue This Year
- QFIN $17.10
- TARS $139.46
- Revenue Next Year
- QFIN $6.28
- TARS $49.91
- P/E Ratio
- QFIN $3.01
- TARS N/A
- Revenue Growth
- QFIN 9.77
- TARS 254.45
- 52 Week Low
- QFIN $20.45
- TARS $38.51
- 52 Week High
- QFIN $48.94
- TARS $76.81
- Technical
- Relative Strength Index (RSI)
- QFIN 39.43
- TARS 58.23
- Support Level
- QFIN $20.67
- TARS $66.31
- Resistance Level
- QFIN $27.59
- TARS $70.07
- Average True Range (ATR)
- QFIN 1.24
- TARS 2.70
- MACD
- QFIN -0.31
- TARS -0.80
- Stochastic Oscillator
- QFIN 44.92
- TARS 35.19
About QFIN Qifu Technology Inc.
Qfin Holdings Inc Formerly Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.